1933 Industries Reports Profit in Q3 2024 Financials
1933 Industries reported its Q3 2024 financial results, showing a significant turnaround with a net profit of $0.1 million, compared to a net loss of $3.3 million in Q3 2023. Total revenues for Q3 reached $4.9 million, a rise from $4.1 million in Q3 2023, while year-to-date (YTD) revenues were $15.1 million, up from $13.3 million the previous year.
The company achieved a gross profit of $2.3 million in Q3 2024, reversing a gross loss of $1.6 million from the prior year, driven by operational efficiencies and facility upgrades. Adjusted EBITDA for YTD was a positive $0.7 million, compared to a loss of $2.6 million in 2023.
1933 Industries' AMA brand ranked #1 in flower and concentrates sales in Nevada. However, operating expenses increased to $2.2 million in Q3 2024, up from $1.8 million in Q3 2023. The company also renegotiated convertible debentures maturing in December 2023, extending maturity to 2025.
Additionally, the company suspended its Canna Hemp™ CBD division and announced a private placement to raise up to $1.8 million, preparing for potential industry changes regarding cannabis rescheduling in the U.S.
- Q3 2024 net profit of $0.1 million compared to a net loss of $3.3 million in Q3 2023.
- Total revenues for Q3 2024 increased to $4.9 million from $4.1 million in Q3 2023.
- Year-to-date (YTD) revenues rose to $15.1 million from $13.3 million in the previous year.
- Gross profit of $2.3 million in Q3 2024, reversing a gross loss of $1.6 million in Q3 2023.
- Adjusted EBITDA of $0.7 million YTD compared to a loss of $2.6 million in 2023.
- AMA brand ranked #1 in flower and concentrates sales in Nevada.
- Operating expenses increased to $2.2 million in Q3 2024 from $1.8 million in Q3 2023.
- Suspension of the Canna Hemp™ CBD division due to declining market demand and competition.
VANCOUVER, BC / ACCESSWIRE / July 2, 2024 / 1933 Industries Inc. (the "Company" or "1933 Industries") (CSE:TGIF)(OTCQB:TGIFF), a Nevada-focused cannabis cultivator and producer, is pleased to announce its unaudited interim consolidated financial statements for the three and nine months ended April 30, 2024 and 2023 ("Q3 2024"). All amounts expressed are in Canadian dollars.
The Company owns
Q3 2024 Financial Highlights
Total revenues of
$4.9 million for Q3 and$15.1 million YTDGross profit of
$2.3 million and$5.4 million YTDNet profit of
$0.1 million compared to a net loss of$3.3 million in 2023Adjusted EBITDA was an income of
$0.7 million YTD compared to a loss of$2.6 million in 2023Top selling cannabis brand in Nevada [1]
#1 Flower rank
#1 Concentrate rank
#3 Pre-Roll rank
Management Commentary
"The increase in revenue, gross margin, and net profit this quarter is a direct result of the strategic measures undertaken over the last year to optimize our cultivation and drive operational efficiencies. While there are always challenges affecting the overall cannabis industry, the Company continues to work towards achieving sustainable profitability, and this quarter was a reliable indication that we are on the right track", said Mr. Paul Rosen, Chairman and CEO of the Company.
"The AMA brand continues to enjoy robust sales in Nevada, with strong brand presence and consumer loyalty. We have been able to achieve this by building trusted relationships with both our customers and our retail clients over the years, and by providing a strong value proposition based on quality, consistency, and high touch customer service", stated Ms. Ester Vigil, President and Director of Sales at 1933 Industries.
According to Headset, a business intelligence aggregator for cannabis retailers, AMA "has shown remarkable consistency and dominance in the Nevada market, particularly in the Concentrates category, where it has maintained the top rank for four consecutive months. This consistency in ranking suggests a strong brand presence and consumer loyalty in this category. In the Flower category, the brand experienced a notable improvement, climbing to the number one spot in April 2024 before settling back to the second position in May 2024. This fluctuation indicates competitive dynamics in the Flower market but also highlights the brand's ability to lead in high-demand categories. In the Pre-Roll segment, AMA has maintained a steady third position from February to May 2024, reflecting a stable performance" [2] .
Q3 2024 and Q3 2023 Consolidated Operating Highlights
Revenues
In Q3 2024, total revenues were
Gross Profit
The Company generated gross profit of
Expenses
During the reporting period, expenses were
Net Profit/Loss
Company-wide, Q3 2024 net earnings were
Q3 2024 Key Developments
On December 29, 2023, the Company announced the renegotiation of its convertible debentures with an original maturity date of December 31, 2023. Of the total principal of
The Company suspended its Canna Hemp™ CBD consumer packaged goods subsidiary while it assesses the viability of the CBD market going forward. The market demand for hemp-infused CBD products has continued to decrease since the COVID pandemic, primarily due to increased competition, the closure of brick-and-mortar stores, and customers exiting the CBD category. The lack of federal rules on CBD products, and the grey area surrounding the introduction of psychoactive Delta 8 compounds into products under the ambiguity of the Farm Bill continue to erode the traditional CBD market and hinder future growth.
The Company announced that its wholly owned subsidiary, FN Pharmaceuticals, entered into a Membership Interest Purchase Agreement to acquire from the Company's then Executive VP and General Counsel, Caleb Zobrist, his nine percent (
Subsequent to the reporting period, the Company announced its intention to complete a non-brokered private placement financing consisting of a maximum of 120,000,000 Units, at a price of
The Company believes that the changing climate in the United States regarding the proposed reclassification of cannabis as a Schedule III controlled substance, will have an overall positive impact in the industry. It is expected that the US Department of Justice under President Joe Biden will reschedule cannabis as a substance of lower risk, thereby recognizing the potential medicinal benefits of the plant
Financial statements are prepared in accordance with International Financial Reporting Standards. Detailed information regarding the Company's financial results as well as management's discussion and analysis can be found at:
https://sedar.com/ and https://1933industries.com/investors/financial-information
In accordance with the continuous disclosure schedule set out by the British Columbia Securities Commission, the Company will release its audited fourth quarter and year-end financial report by November 28, 2024.
About 1933 Industries Inc.
1933 Industries is a Nevada-based licensed producer, focused on the cultivation and extraction of a large portfolio of cannabis consumer products in a variety of formats under its flagship brands, Alternative Medicine Association (AMA) and Level X. Its product offerings are cultivated at the Company's 68,000 sq. ft. indoor facility and marketed directly to retail dispensaries. AMA branded flower, infused pre-rolls, and in-house boutique concentrates consistently rank as the top products sold in Nevada. For more information, please visit www.1933industries.com
For further information please contact:
Alexia Helgason, VP, Investor Relations
604-728-4407
alexia@1933industries.com
Paul Rosen, CEO
paul@1933industries.com
Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.
Notice regarding Forward Looking Statements: This news release contains forward-looking statements. The use of any of the words "anticipate", "continue", "estimate", "expect", "may", "will", "project", "should", "believe" and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this news release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company's disclosure documents, which can be found under the Company's profile on www.sedar.com . 1933 Industries undertakes no obligation to update publicly or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by law.
[1] https://www.headset.io/brands/alternative-medicine-association-ama
[2] https://www.headset.io/brands/alternative-medicine-association-ama
SOURCE: 1933 Industries Inc.
View the original press release on accesswire.com
FAQ
What were 1933 Industries' total revenues for Q3 2024?
Did 1933 Industries report a profit or loss in Q3 2024?
How did 1933 Industries' AMA brand perform in Nevada?
What is the status of 1933 Industries' Canna Hemp™ CBD division?
What was 1933 Industries' Adjusted EBITDA for the nine months ended April 30, 2024?